Daniel H. White Sells 8,000 Shares of Clearside Biomedical, Inc. (CLSD) Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD) insider Daniel H. White sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were sold at an average price of $7.89, for a total value of $63,120.00. Following the completion of the transaction, the insider now directly owns 504,067 shares of the company’s stock, valued at $3,977,088.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Clearside Biomedical, Inc. (NASDAQ:CLSD) traded up 0.52% during midday trading on Friday, hitting $7.79. The company’s stock had a trading volume of 85,647 shares. The firm’s market cap is $197.09 million. Clearside Biomedical, Inc. has a 12 month low of $5.44 and a 12 month high of $25.08. The company’s 50 day moving average price is $7.87 and its 200 day moving average price is $8.47.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings data on Wednesday, May 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.03. Clearside Biomedical had a negative net margin of 154,030.02% and a negative return on equity of 53.20%. The firm had revenue of $0.01 million during the quarter. Analysts expect that Clearside Biomedical, Inc. will post ($1.72) EPS for the current year.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by sleekmoney and is the property of of sleekmoney. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://sleekmoney.com/daniel-h-white-sells-8000-shares-of-clearside-biomedical-inc-clsd-stock/1915904.html.

Several large investors have recently modified their holdings of CLSD. Wellington Management Group LLP increased its stake in shares of Clearside Biomedical by 31.6% in the first quarter. Wellington Management Group LLP now owns 2,164,703 shares of the company’s stock worth $17,187,000 after buying an additional 520,403 shares during the last quarter. FMR LLC increased its stake in shares of Clearside Biomedical by 377.3% in the fourth quarter. FMR LLC now owns 1,029,600 shares of the company’s stock worth $9,205,000 after buying an additional 813,889 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Clearside Biomedical during the fourth quarter worth about $6,365,000. Vanguard Group Inc. increased its stake in shares of Clearside Biomedical by 7.8% in the first quarter. Vanguard Group Inc. now owns 631,062 shares of the company’s stock worth $5,011,000 after buying an additional 45,657 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Clearside Biomedical by 181.1% in the fourth quarter. Marshall Wace LLP now owns 449,820 shares of the company’s stock worth $4,021,000 after buying an additional 289,820 shares during the last quarter. 49.69% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently commented on CLSD shares. Zacks Investment Research upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Tuesday, March 7th. Wedbush reiterated an “outperform” rating and issued a $27.00 price objective on shares of Clearside Biomedical in a research note on Tuesday, March 14th. J P Morgan Chase & Co started coverage on Clearside Biomedical in a research note on Friday, February 24th. They issued an “overweight” rating and a $19.00 price objective on the stock. Cowen and Company reiterated a “buy” rating on shares of Clearside Biomedical in a research note on Thursday, June 8th. Finally, Needham & Company LLC dropped their price objective on Clearside Biomedical to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, March 14th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $20.71.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/daniel-h-white-sells-8000-shares-of-clearside-biomedical-inc-clsd-stock/1915904.html

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *